Form 8-K

8-K — Elevance Health, Inc.

Accession: 0001156039-26-000058

Filed: 2026-07-15

Period: 2026-07-15

CIK: 0001156039

SIC: 6324 (HOSPITAL & MEDICAL SERVICE PLANS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — elv-20260715.htm (Primary)

EX-99.1 (a2q2026elvearningsrelease.htm)

GRAPHIC (abs_rxhxrgbxcxaligneda.jpg)

GRAPHIC (elevancehealtha.jpg)

GRAPHIC (image1a.jpg)

GRAPHIC (imagea.jpg)

GRAPHIC (wlp_rxhxrgbxcxaligneda.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: elv-20260715.htm · Sequence: 1

elv-20260715

FALSE000115603900011560392026-07-152026-07-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

July 15, 2026

Date of Report (Date of earliest event reported)

___________________________________

Elevance Health, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Indiana

(State or other jurisdiction of

incorporation or organization)

001-16751

(Commission File Number)

35-2145715

(I.R.S. Employer Identification Number)

220 Virginia Ave

Indianapolis, IN 46204

(Address of principal executive offices and zip code)

(833) 401-1577

(Registrant's telephone number, including area code)

________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, Par Value $0.01

ELV

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 - Results of Operations and Financial Condition.

On July 15, 2026, Elevance Health, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

None of the information furnished in this Item 2.02 or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Exhibit

99.1

Press Release, dated July 15, 2026, reporting Elevance Health, Inc. financial results for the quarter ended June 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 15th day of July, 2026.

ELEVANCE HEALTH, INC.

By:

/s/ Kathleen S. Kiefer

Name:

Kathleen S. Kiefer

Title:

Chief Governance Officer and Corporate Secretary

EX-99.1

Filename: a2q2026elvearningsrelease.htm · Sequence: 2

Document

E A R N I N G S R E L E A S E

ELEVANCE HEALTH REPORTS SECOND QUARTER 2026 RESULTS;

RAISES FULL-YEAR GUIDANCE

•2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025

•2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit

•FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results

•Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions

•FY 2026 operating cash flow guidance raised to at least $6.0 billion

Indianapolis, IN - July 15, 2026 - Elevance Health, Inc. (NYSE: ELV) reported second quarter 2026 results ahead of expectations.

"Our second quarter results exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio. We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider connectivity, operating efficiency, and Carelon’s value-based solutions. These actions will strengthen how we operate, improve consistency over time, and reinforce our confidence in returning to at least 12% adjusted EPS growth in 2027 off our 2026 earnings baseline.”

Gail K. Boudreaux

President and Chief Executive Officer

1.Earnings per diluted share ("EPS").

2.Refer to GAAP reconciliation tables on pages 13 and 14 herein for reconciliation of GAAP to adjusted measures.

Elevance Health

Consolidated Enterprise Highlights

(Unaudited)

(In billions) Three Months Ended

June 30, 2026 June 30, 2025

Operating Revenue1

$49.8 $49.4

Operating Gain1,2

$1.8 $2.4

Adjusted Operating Gain1,3

$1.8 $2.5

Operating Margin1

3.5 % 4.9 %

Adjusted Operating Margin1,3

3.6 % 5.0 %

1.See “Basis of Presentation” on page 5 herein.

2.Operating Gain for the three months ended June 30, 2026, and June 30, 2025, include items that are excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.

3.Adjusted Operating Gain for the three months ended June 30, 2026, and June 30, 2025, exclude items that are excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.

Operating revenue was $49.8 billion in the second quarter of 2026, an increase of $0.4 billion compared to the prior year quarter. This was driven by higher premium yields in our Health Benefits segment and growth in CarelonRx product revenue, partially offset by anticipated declines in our Medicare Advantage, Medicaid, and Employer Group risk membership.

The benefit expense ratio of 89.7 percent increased 80 basis points year over year, driven by expected elevated medical cost trend in our Government businesses, partially offset by improved performance in Individual ACA compared to the prior year.

Days in Claims Payable stood at 45.4 days as of June 30, 2026, a decrease of 1.2 days from March 31, 2026 and an increase of 2.9 days year over year.

The operating expense ratio was 11.1 percent. The adjusted operating expense ratio was 11.0 percent, an increase of 100 basis points, driven primarily by targeted investments in our workforce and in capabilities that support our long-term operating model. We continue to manage expenses thoughtfully while investing in the priorities that strengthen enterprise performance over time.

Cash Flow & Balance Sheet

Operating cash flow of $1.9 billion in the quarter reflects timing of a state Medicaid pass-through payment and underlying business strength. As of June 30, 2026, cash and investments at the parent company totaled approximately $2.1 billion.

During the second quarter of 2026, the Company repurchased 0.7 million shares of its common stock for $234 million, at a weighted average price of $344.62, and paid a quarterly dividend of $1.72 per share, representing a distribution of cash totaling $373 million. As of June 30, 2026, the Company had approximately $5.3 billion of Board approved share repurchase authorization remaining.

Health Benefits is comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses.

Health Benefits

Reportable Segment Highlights

(Unaudited)

(In billions)

Three Months Ended

June 30, 2026 June 30, 2025

Operating Revenue1

$42.7 $41.6

Operating Gain1

$0.9 $1.6

Operating Margin1

2.1 % 3.8 %

1.See “Basis of Presentation” on page 5 herein.

Health Benefits segment operating revenue was $42.7 billion in the second quarter of 2026, an increase of $1.1 billion, or 3 percent compared to the prior year quarter, driven primarily by higher premium yields, partially offset by expected declines in our Medicare Advantage, Medicaid, and Employer Group risk membership.

Operating gain was $0.9 billion, a decrease year over year, reflecting higher benefit expense and targeted investments to support our workforce and strengthen enterprise performance, partially offset by operating revenue growth.

Medical membership of approximately 44.9 million as of June 30, 2026 decreased by 469 thousand sequentially, driven by a known commercial fee-based customer transition and anticipated attrition in our Individual ACA and Medicaid membership.

Carelon is comprised of CarelonRx and Carelon Services.

Carelon

Reportable Segment Highlights

(Unaudited)

(In billions)

Three Months Ended

June 30, 2026 June 30, 2025

Operating Revenue1

$19.2 $18.1

Operating Gain1

$0.9 $0.9

Operating Margin1

4.9 % 5.2 %

1.See “Basis of Presentation” on page 5 herein.

Operating revenue for Carelon was $19.2 billion in the second quarter of 2026, an increase of $1.1 billion, or 6 percent compared to the prior year quarter. Growth was driven by the scaling of Carelon Services risk-based solutions and CarelonRx product revenue.

Operating gain for Carelon totaled $0.9 billion, an increase of 1 percent year over year, reflecting improved profitability in our specialty pharmacy.

Quarterly Dividend

On July 14, 2026, the Audit Committee of the Company's Board of Directors declared a third quarter 2026 dividend to shareholders of $1.72 per share. The third quarter dividend is payable on September 25, 2026, to shareholders of record at the close of business on September 10, 2026.

About Elevance Health

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 104 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

Conference Call and Webcast

Management will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time (“EDT”) to discuss the company’s second quarter results and outlook. The conference call should be accessed at least 15 minutes prior to the start of the call with the following numbers:

888-947-9963 (Domestic)

800-391-9853 (Domestic Replay)

312-470-0178 (International)

203-369-3269 (International Replay)

The access code for today's conference call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT today, until the end of the day on August 14, 2026. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A webcast replay will be available following the call.

Basis of Presentation

1.Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Refer to pages 13 and 14 for the GAAP reconciliation tables.

2.Operating margin is defined as operating gain divided by operating revenue.

Elevance Health Contacts:

Investor Relations

Media

Nathan Rich

Leslie Porras

Investor.Relations@elevancehealth.com

Leslie.Porras@elevancehealth.com

Elevance Health

Earnings Release Financial Schedules and Supplementary Information

Quarter & Year-to-Date Ended June 30, 2026

•Membership and Other Metrics

•Quarterly & Year-to-Date Consolidated Statements of Income

•Condensed Consolidated Balance Sheet

•Condensed Consolidated Statement of Cash Flows

•Supplemental Financial Information - Reportable Segments & Health Benefits Revenue Details

•Supplemental Financial Information - Reconciliation of Medical Claims Payable

•Reconciliation of Non-GAAP Financial Measures

Elevance Health

Membership and Other Metrics

(Unaudited)

Change from

Medical Membership (in thousands) June 30,

2026 June 30,

2025 March 31,

2026 June 30,

2025 March 31,

2026

Individual 1,317 1,348 1,424 (2.3) % (7.5) %

Employer Group Risk-Based 3,417 3,615 3,439 (5.5) % (0.6) %

Commercial Risk-Based 4,734 4,963 4,863 (4.6) % (2.7) %

BlueCard®

6,582 6,570 6,579 0.2 % — %

Employer Group Fee-Based 20,931 20,584 21,170 1.7 % (1.1) %

Commercial Fee-Based 27,513 27,154 27,749 1.3 % (0.9) %

Medicare Advantage 1,897 2,255 1,899 (15.9) % (0.1) %

Medicare Supplement 893 874 888 2.2 % 0.6 %

Total Medicare 2,790 3,129 2,787 (10.8) % 0.1 %

Medicaid 8,358 8,733 8,456 (4.3) % (1.2) %

Federal Employee Program

1,554 1,642 1,563 (5.4) % (0.6) %

Total Medical Membership 44,949 45,621 45,418 (1.5) % (1.0) %

Other Metrics (in millions)

CarelonRx Quarterly Adjusted Scripts 80.9 83.3 80.3 (2.9) % 0.7 %

Carelon Services Consumers Served 92.4 97.3 92.9 (5.0) % (0.5) %

Elevance Health

Consolidated Statements of Income

(Unaudited)

(In millions, except per share data) Three Months Ended

June 30 Six Months Ended

June 30

2026 2025 Change 2026 2025 Change

Revenues

Premiums

$ 41,279 $ 41,271 —% $ 82,303 $ 82,158 0.2%

Product revenue 6,264 6,042 3.7% 12,489 11,851 5.4%

Service fees 2,283 2,108 8.3% 4,528 4,177 8.4%

Total operating revenue 49,826 49,421 0.8% 99,320 98,186 1.2%

Net investment income 704 486 44.9% 1,469 1,076 36.5%

Net losses on financial instruments (56) (131) NM (134) (595) NM

Total revenues 50,474 49,776 1.4% 100,655 98,667 2.0%

Expenses

Benefit expense 37,024 36,706 0.9% 72,639 72,018 0.9%

Cost of products sold 5,492 5,293 3.8% 10,955 10,276 6.6%

Operating expense 5,547 4,997 11.0% 11,877 10,297 15.3%

Interest expense 364 341 6.7% 721 685 5.3%

Amortization of other intangible assets 110 147 (25.2)% 222 302 (26.5)%

Total expenses 48,537 47,484 2.2% 96,414 93,578 3.0%

Income before income tax expense 1,937 2,292 (15.5)% 4,241 5,089 (16.7)%

Income tax expense 483 548 (11.9)% 1,027 1,161 (11.5)%

Net income 1,454 1,744 (16.6)% 3,214 3,928 (18.2)%

Net loss (gain) attributable to noncontrolling interests 9 (1) NM 13 (2) NM

Shareholders' net income $ 1,463 $ 1,743 (16.1)% $ 3,227 $ 3,926 (17.8)%

Shareholders' earnings per diluted share

$ 6.71 $ 7.72 (13.1)% $ 14.73 $ 17.33 (15.0)%

Diluted shares 217.9 225.8 (3.5)% 219.1 226.5 (3.3)%

Benefit expense as a percentage of premiums 89.7 % 88.9 % 80 bp 88.3 % 87.7 % 60 bp

Operating expense as a percentage of total operating revenue 11.1 % 10.1 % 100 bp 12.0 % 10.5 % 150 bp

Income before income tax expense as a percentage of total revenue 3.8 % 4.6 % (80) bp 4.2 % 5.2 % (100) bp

"NM" = calculation not meaningful

Elevance Health

Condensed Consolidated Balance Sheet

(In millions) June 30,

2026 December 31,

2025

Assets (Unaudited)

Current assets:

Cash and cash equivalents $10,232 $9,491

Fixed maturity and equity securities 27,282 26,624

Premium and other receivables 23,392 21,542

Other current assets 6,278 5,344

Total current assets 67,184 63,001

Long-term investments 12,389 11,960

Property and equipment, net 4,645 4,679

Goodwill and other intangible assets 39,322 39,544

Other noncurrent assets 2,898 2,310

Total assets $126,438 $121,494

Liabilities and equity

Liabilities

Current liabilities:

Medical claims payable $18,463 $17,084

Short-term borrowings — 150

Current portion of long-term debt 375 1,099

Other current liabilities 25,416 22,702

Total current liabilities 44,254 41,035

Long-term debt, less current portion 30,669 30,797

Other noncurrent liabilities 6,493 5,636

Total liabilities 81,416 77,468

Total shareholders’ equity 44,883 43,882

Noncontrolling interests 139 144

Total equity 45,022 44,026

Total liabilities and equity $126,438 $121,494

Elevance Health

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(In millions) Six Months Ended June 30

2026 2025

Operating activities

Net income $3,214 $3,928

Depreciation and amortization 720 753

Share-based compensation 130 162

Changes in operating assets and liabilities 2,700 (2,003)

Other non-cash items (519) 231

Net cash provided by operating activities 6,245 3,071

Investing activities

Sales and maturities of investments, net of purchases (purchases of investments, net of sales and maturities) (813) 329

Purchases of subsidiaries, net of cash acquired 5 54

Purchases of property and equipment (522) (463)

Other, net (153) (504)

Net cash used in investing activities (1,483) (584)

Financing activities

Net change in short-term and long-term borrowings (900) (1,255)

Repurchase and retirement of common stock (1,358) (1,258)

Cash dividends (749) (771)

Other, net (1,002) 1,067

Net cash used in financing activities (4,009) (2,217)

Effect of foreign exchange rates on cash and cash equivalents (12) 2

Change in cash and cash equivalents 741 272

Cash and cash equivalents at beginning of period 9,491 8,288

Cash and cash equivalents at end of period $10,232 $8,560

REPORTABLE SEGMENTS

Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not allocated to our other reportable segments).

Elevance Health

Reportable Segment Details

(Unaudited)

(In millions) Three Months Ended June 30 Six Months Ended June 30

2026 2025 Change 2026 2025 Change

Operating Revenue

Health Benefits $42,720 $41,582 2.7 % $85,210 $83,013 2.6 %

CarelonRx 11,250 10,643 5.7 % 21,850 20,759 5.3 %

Carelon Services 7,975 7,441 7.2 % 15,340 13,977 9.8 %

Corporate & Other 6 232 (97.4) % 10 397 (97.5) %

Eliminations (12,125) (10,477)

NM6

(23,090) (19,960)

NM6

Total Operating Revenue1

$49,826 $49,421 0.8 % $99,320 $98,186 1.2 %

Operating Gain (Loss)

Health Benefits $896 $1,560 (42.6) % $3,053 $3,777 (19.2) %

CarelonRx 582 536 8.6 % 1,164 1,138 2.3 %

Carelon Services 366 400 (8.5) % 836 891 (6.2) %

Corporate & Other2,3

(81) (71)

NM6

(1,204) (211)

NM6

Total Operating Gain1,4

$1,763 $2,425 (27.3) % $3,849 $5,595 (31.2) %

Operating Margin

Health Benefits 2.1 % 3.8 % (170) bp 3.6 % 4.5 % (90) bp

CarelonRx 5.2 % 5.0 % 20 bp 5.3 % 5.5 % (20) bp

Carelon Services 4.6 % 5.4 % (80) bp 5.4 % 6.4 % (100) bp

Total Operating Margin1

3.5 % 4.9 % (140) bp 3.9 % 5.7 % (180) bp

Health Benefits Revenue Details

(In millions) Three Months Ended June 30 Six Months Ended June 30

2026 2025 Change 2026 2025 Change

Health Benefits Operating Revenue

Commercial $13,561 $12,453 8.9 % $26,799 $24,805 8.0 %

Individual5

2,720 2,328 16.8 % 5,260 4,689 12.2 %

Medicare 10,962 11,446 (4.2) % 21,953 22,852 (3.9) %

Medicaid 14,444 13,911 3.8 % 28,724 27,954 2.8 %

Federal Employee Program 3,753 3,772 (0.5) % 7,734 7,402 4.5 %

Total Health Benefits Operating Revenue1

$42,720 $41,582 2.7 % $85,210 $83,013 2.6 %

1.See “Basis of Presentation” on page 5 herein.

2.Operating Gain for the three and six months ended June 30, 2026 included $44 and $91 million, respectively, of transaction and integration related costs, and $11 and $18 million, respectively, of litigation and settlement expenses. Operating Gain for the six months ended June 30, 2026 also included $935 million for the Company's current best estimate of the identified potential exposure for certain historical Medicare Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026, and $129 million of business optimization program charges. All adjustments for the three and six month periods reside in the Corporate & Other reportable segment.

3.Operating Gain for the three and six months ended June 30, 2025, included $53 and $133 million, respectively, of transaction and integration related costs and $10 and $15 million, respectively, of litigation and settlement expenses, which reside in the Corporate & Other reportable segment.

4.Operating Gain for the three and six months ended June 30, 2026, and June 30, 2025, include items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.

5.The Individual business, including ACA products, is reported as part of Commercial Operating Revenue.

6."NM" = calculation not meaningful.

Elevance Health

Reconciliation of Medical Claims Payable

Six Months Ended June 30 Years Ended December 31

2026 2025 2025 2024 2023

(In millions) (Unaudited) (Unaudited)

Gross medical claims payable, beginning of period $ 16,829 $ 15,580 $ 15,580 $ 15,865 $ 15,348

Ceded medical claims payable, beginning of period (48) (13) (13) (7) (6)

Net medical claims payable, beginning of period 16,781 15,567 15,567 15,858 15,342

Business combinations and purchase adjustments — 182 344 143 —

Net incurred medical claims:

Current year 71,743 71,090 145,566 125,370 121,798

Prior years redundancies1

(1,195) (1,065) (1,290) (1,731) (1,571)

Total net incurred medical claims 70,548 70,025 144,276 123,639 120,227

Net payments attributable to:

Current year medical claims 56,610 57,117 130,265 110,930 107,146

Prior years medical claims 12,619 11,802 13,141 13,143 12,565

Total net payments 69,229 68,919 143,406 124,073 119,711

Net medical claims payable, end of period 18,100 16,855 16,781 15,567 15,858

Ceded medical claims payable, end of period 44 16 48 13 7

Gross medical claims payable, end of period2

$ 18,144 $ 16,871 $ 16,829 $ 15,580 $ 15,865

Current year medical claims paid as a percentage of current year net incurred medical claims 78.9 % 80.3 % 89.5 % 88.5 % 88.0 %

Prior year redundancies in the current year as a percentage of prior year net medical claims payable less prior year redundancies in the current year 7.7 % 7.3 % 9.0 % 12.3 % 11.4 %

Prior year redundancies in the current year as a percentage of prior year net incurred medical claims 0.8 % 0.9 % 1.0 % 1.4 % 1.4 %

1.Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated.

2.Excludes insurance lines other than short duration.

Elevance Health

GAAP Reconciliation

(Unaudited)

This document references non-GAAP measures, including “Adjusted Diluted EPS,” “Adjusted Operating Expense Ratio,” “Adjusted Operating Gain,” “Adjusted Operating Margin,” “Adjusted Shareholders’ Net Income,” and “Adjusted Operating Expense”. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available below. In addition to these non-GAAP measures, references are made to the measures “Operating Revenue,” “Operating Gain/Loss,” and “Operating Margin”. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reportable segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein. A reconciliation of reportable segments operating gain to income before income tax expense is provided below. Prior amounts may be grouped differently to conform to the current presentation. Net adjustment items per share may not sum due to rounding.

Three Months Ended June 30 Six Months Ended June 30

(In millions, except per share data) 2026 2025 Change 2026 2025 Change

Shareholders' net income $ 1,463 $ 1,743 (16.1) % $ 3,227 $ 3,926 (17.8) %

Add / (Subtract):

Amortization of other intangible assets 110 147 222 302

Net losses on financial instruments 56 131 134 595

Transaction and integration related costs1

44 53 91 133

Litigation and settlement expenses1

11 10 18 15

Accrual related to CMS notice1,2

— — 935 —

Business optimization program charges1

— — 129 —

Tax impact of non-GAAP adjustments (60) (87) (360) (255)

Net adjustment items 161 254 1,169 790

Adjusted shareholders' net income $ 1,624 $ 1,997 (18.7) % $ 4,396 $ 4,716 (6.8) %

Shareholders' earnings per diluted share $ 6.71 $ 7.72 (13.1) % $ 14.73 $ 17.33 (15.0) %

Add / (Subtract):

Amortization of other intangible assets 0.50 0.65 1.01 1.33

Net losses on financial instruments 0.26 0.58 0.61 2.63

Transaction and integration related costs1

0.20 0.23 0.42 0.59

Litigation and settlement expenses1

0.05 0.04 0.08 0.07

Accrual related to CMS notice1,2

— — 4.27 —

Business optimization program charges1

— — 0.59 —

Tax impact of non-GAAP adjustments (0.28) (0.39) (1.64) (1.13)

Net adjustment items 0.74 1.12 5.33 3.49

Adjusted shareholders' earnings per diluted share

$ 7.45 $ 8.84 (15.7) % $ 20.06 $ 20.82 (3.7) %

Three Months Ended June 30 Six Months Ended June 30

(In millions) 2026 2025 Change 2026 2025 Change

Income before income tax expense $ 1,937 $ 2,292 (15.5) % $ 4,241 $ 5,089 (16.7) %

Net investment income (704) (486) (1,469) (1,076)

Interest expense 364 341 721 685

Amortization of other intangible assets 110 147 222 302

Net losses on financial instruments 56 131 134 595

Reportable segments operating gain $ 1,763 $ 2,425 (27.3) % $ 3,849 $ 5,595 (31.2) %

1.Adjustment item resides in the Corporate & Other reportable segment.

2.Adjustment item represents the Company's current best estimate of the identified potential exposure for certain historical Medicare Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026.

Elevance Health

GAAP Reconciliation

(Unaudited)

Three Months Ended June 30 Six Months Ended June 30

(In millions) 2026 2025 Change 2026 2025 Change

Reportable segments operating gain $ 1,763 $ 2,425 (27.3) % $ 3,849 $ 5,595 (31.2) %

Add / (Subtract):

Transaction and integration related costs1

44 53 91 133

Litigation and settlement expenses1

11 10 18 15

Accrual related to CMS notice1,2

— — 935 —

Business optimization program charges1

— — 129 —

Net adjustment items

55 63 1,173 148

Reportable segments adjusted operating gain $ 1,818 $ 2,488 (26.9) % $ 5,022 $ 5,743 (12.6) %

Operating revenue $ 49,826 $ 49,421 0.8 % $ 99,320 $ 98,186 1.2 %

Operating margin 3.5 % 4.9 % (140) bp 3.9 % 5.7 % (180) bp

Adjusted operating margin 3.6 % 5.0 % (140) bp 5.1 % 5.8 % (70) bp

Three Months Ended June 30 Six Months Ended June 30

(In millions) 2026 2025 Change 2026 2025 Change

Operating expense $ 5,547 $ 4,997 11.0 % $ 11,877 $ 10,297 15.3 %

Add / (Subtract):

Transaction and integration related costs1

(44) (53) (91) (133)

Litigation and settlement expenses1

(11) (10) (18) (15)

Accrual related to CMS notice1,2

— — (935) —

Business optimization program charges1

— — (129) —

Net adjustment items (55) (63) (1,173) (148)

Adjusted operating expense $ 5,492 $ 4,934 11.3 % $ 10,704 $ 10,149 5.5 %

Operating revenue $ 49,826 $ 49,421 0.8 % $ 99,320 $ 98,186 1.2 %

Operating expense ratio 11.1 % 10.1 % 100 bp 12.0 % 10.5 % 150 bp

Adjusted operating expense ratio 11.0 % 10.0 % 100 bp 10.8 % 10.3 % 50 bp

Full Year 2026 Outlook

Shareholders' earnings per diluted share At least $20.10

Add / (Subtract):

Accrual related to CMS notice1,2

$4.27

Amortization of other intangible assets3

$2.00

Net losses on financial instruments3

$1.15

Transaction and integration related costs1,3

$0.90

Business optimization program charges1

$0.59

Litigation and settlement expenses1,3

$0.10

Tax impact of non-GAAP adjustments3

Approximately ($2.11)

Net adjustment items $6.90

Adjusted shareholders' earnings per diluted share At least $27.00

1.Adjustment item resides in the Corporate & Other reportable segment.

3.Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.

Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan,” "potential," "predict" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

GRAPHIC

Filename: abs_rxhxrgbxcxaligneda.jpg · Sequence: 7

Binary file (35919 bytes)

Download abs_rxhxrgbxcxaligneda.jpg

GRAPHIC

Filename: elevancehealtha.jpg · Sequence: 8

Binary file (15573 bytes)

Download elevancehealtha.jpg

GRAPHIC

Filename: image1a.jpg · Sequence: 9

Binary file (639509 bytes)

Download image1a.jpg

GRAPHIC

Filename: imagea.jpg · Sequence: 10

Binary file (115835 bytes)

Download imagea.jpg

GRAPHIC

Filename: wlp_rxhxrgbxcxaligneda.jpg · Sequence: 11

Binary file (27393 bytes)

Download wlp_rxhxrgbxcxaligneda.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 13

v3.26.1

Document and Entity Information

Jul. 15, 2026

Document and Entity Information [Line Items]

Amendment Flag

false

Entity Central Index Key

0001156039

Document Type

8-K

Document Period End Date

Jul. 15, 2026

Entity Registrant Name

Elevance Health, Inc.

Entity Incorporation, State or Country Code

Entity File Number

001-16751

Entity Tax Identification Number

35-2145715

Entity Address, Address Line One

220 Virginia Ave

Entity Address, City or Town

Indianapolis

Entity Address, State or Province

Entity Address, Postal Zip Code

46204

City Area Code

833

Local Phone Number

401-1577

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, Par Value $0.01

Trading Symbol

ELV

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration